Compare Stocks → This company has increased its dividend every year for 54 years (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVEONASDAQ:ETONNASDAQ:MBIONASDAQ:MLND Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsETONEton Pharmaceuticals$3.06$4.00$2.42▼$5.81$78.61M1.1768,630 shs18,441 shsMBIOMustang Bio$0.36-3.0%$1.04$0.33▼$8.17$3.74M1.58176,162 shs59,559 shsMLNDMillendo Therapeutics$3.17-3.1%$4.00$0.92▼$16.95$60.37M0.481.52 million shs316,619 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ETONEton Pharmaceuticals-2.55%-11.05%-13.56%-26.09%-16.16%MBIOMustang Bio-3.39%-32.20%-64.50%-72.52%-90.82%MLNDMillendo Therapeutics-2.39%-15.06%-15.50%-17.01%+47.96%Bitcoin Rockets To Record High But Buy THIS Instead (Ad)Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AETONEton Pharmaceuticals2.3425 of 5 stars3.55.00.00.02.70.80.0MBIOMustang Bio1.6318 of 5 stars3.55.00.00.01.60.00.0MLNDMillendo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO PharmaceuticalsN/AN/AN/AN/AETONEton Pharmaceuticals3.00Buy$10.00226.80% UpsideMBIOMustang Bio3.00Buy$17.254,691.67% UpsideMLNDMillendo TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28ETONEton Pharmaceuticals$31.64M2.48$0.00 per share982.54$0.60 per share5.10MBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/AMLNDMillendo TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/AETONEton Pharmaceuticals-$940K-$0.03N/A∞N/A-2.96%-6.21%-3.17%5/9/2024 (Estimated)MBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)MLNDMillendo Therapeutics-$36.41MN/A0.00∞N/AN/A-91.03%-72.44%N/ALatest MLND, AVEO, MBIO, and ETON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023ETONEton Pharmaceuticals-$0.04-$0.09-$0.05-$0.09$7.70 million$7.31 million 3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/AMLNDMillendo TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35ETONEton PharmaceuticalsN/A1.651.60MBIOMustang BioN/A0.740.74MLNDMillendo TherapeuticsN/A6.396.39OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%ETONEton Pharmaceuticals27.86%MBIOMustang Bio9.95%MLNDMillendo TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%ETONEton Pharmaceuticals13.16%MBIOMustang Bio2.10%MLNDMillendo TherapeuticsN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableETONEton Pharmaceuticals3025.69 million22.31 millionOptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionableMLNDMillendo Therapeutics1219.04 millionN/ANot OptionableMLND, AVEO, MBIO, and ETON HeadlinesSourceHeadlineA lifesaving therapy for children with a rare disease is now the world’s most expensive drug, raising questions about accessmsn.com - March 20 at 4:34 PMMind Medicine sends psychedelic stocks higher after FDA status for LSD formulationmsn.com - March 7 at 1:33 PMClearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placementmarkets.businessinsider.com - January 11 at 10:32 AMWhy Is Clearmind Medicine (CMND) Stock Up 50% Today?msn.com - December 5 at 2:48 PMMaxim Group Maintains Their Buy Rating on Mind Medicine (MMED)markets.businessinsider.com - November 6 at 11:34 PMWhat to Look For in the Pipeline, Misconceptions of Drug Approvals and More of ‘What’s on the Mind’ of Jeffrey Casbergmanagedhealthcareexecutive.com - June 15 at 1:06 PMNumab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Programeagletribune.com - May 15 at 7:56 AMMindBio Therapeutics Corp (CSE: MBIO) Reveals Scientific Paper in World-First Take-Home, LSD-Microdosing Clinical Trial in 80 Healthy Participantssports.yahoo.com - May 10 at 2:53 PMExpert Ratings for Decibel Therapeuticsbenzinga.com - March 15 at 2:08 PMIterum Therapeutics plc (NASDAQ:ITRM) Q3 2022 Earnings Call Transcriptinsidermonkey.com - December 29 at 7:53 AMClearmind Medicine Announces Shareholders Meeting Resultsyahoo.com - December 29 at 7:53 AMClearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in Indiafinance.yahoo.com - June 3 at 8:33 AMDTx Pharma Appoints Michael Huang, MD as Chief Medical Officerfinance.yahoo.com - May 31 at 10:27 AMClearmind Announces Successful Pre-IND Meeting with U.S. FDA for CMND-100 for Alcohol Use Disorderkoin.com - May 26 at 10:15 AMClearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumptionfinance.yahoo.com - May 19 at 9:05 AMMind Medicine(MNMD) CEO Rob Barrow on Q1 2022 Results - Earnings Call Transcriptseekingalpha.com - May 16 at 4:07 PMClearmind Announces Pre-IND Meeting Date with FDAfinance.yahoo.com - May 15 at 3:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAVEO PharmaceuticalsNASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Eton PharmaceuticalsNASDAQ:ETONEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Millendo TherapeuticsNASDAQ:MLNDAs of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.